Nanoemulsion therapeutic compositions and methods of using the same
The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia ) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.
1. A method of treating inflammation and edema associated with a burn wound, comprising:
A) providing
i) a subject harboring a burn wound; and
ii) a composition comprising a nanoemulsion, wherein said nanoemulsion comprises:
1. 30-90%, 60-80%, or 60-70% by volume oil;
2. 3-15% by volume solvent; wherein said solvent is selected from the group consisting of ethanol and glycerol;
3. 0.05-10.0% by volume non-ionic surfactant and 0.001-5.0% by volume cationic surfactant;
4. ethylenediaminetetraacetic acid (EDTA); and
5. water; and
B) administering said composition comprising a nanoemulsion to said burn wound, wherein said administering reduces inflammation and edema at the site of said burn wound.
2. The method of claim 1 , wherein said administering reduces, attenuates and/or prevents bacterial growth in said burn wound.
3. The method of claim 1 , wherein said nanoemulsion comprises
a) water;
b) a non-ionic surfactant selected from the group consisting of polyoxyethylenesorbitan monolaurate, polyoxyethylenesorbitan monooleate, and a poloxamer;
c) ethanol;
d) oil;
e) a cationic surfactant selected from the group consisting of cetylpyridinium chloride (CPC), benzalkonium chloride, and alkyl dimethyl benzyl ammonium chloride; and
f). ethylenediaminetetraacetic acid (EDTA).
4. The method of claim 1 , wherein said composition comprises a dilution of said nanoemulsion to a 10% formulation, wherein said 10% formulation is generated by combining 76 g water per 24 g 100 mM EDTA per 20 g 60% of nanoemulsion.
5. The method of claim 1 , wherein said administering reduces the occurrence of shock, pulmonary dysfunction, abdominal or extremity compartment syndrome, or cardiac failure in said subject.
6. The method of claim 1 , wherein said composition is co-administered with an antimicrobial agent or an anti-inflammatory agent.
7. The method of claim 6 , wherein said antimicrobial agent is an antibiotic.
8. The method of claim 6 , wherein said anti-inflammatory agent is selected from the group consisting of silver nitrate (AgNO 3 ), silver sulfadiazine, mafenide acetate, nanocrystalline impregnated silver dressings, and a p38 MAPK inhibitor.
9. A method of treating an infection of a burn wound comprising administering a composition comprising a nanoemulsion, or a dilution thereof, wherein the nanoemulsion comprises:
1. 30-90%, 60-80%, or 60-70% by volume oil;
2. 3-15% by volume solvent; wherein said solvent is selected from the group consisting of ethanol and glycerol;
3. 0.05-10.0% by volume non-ionic surfactant and 0.001-5.0% by volume cationic surfactant;
4. ethylenediaminetetraacetic acid (EDTA); and
5. water
to said burn wound, wherein said composition kills or inhibits growth of bacteria within the burn wound infection in the absence of increased inflammation and edema at the site of the burn wound.
10. The method of claim 9 , wherein said burn wound infection comprises Staphylococcus aureus.
11. The method of claim 10 , wherein said Staphylococcus aureus are antibiotic resistant.
12. The method of claim 9 , wherein said burn wound infection comprises Pseudomonas aeruginosa.
13. The method of claim 9 , wherein said burn wound is selected from the group consisting of a superficial burn wound and a partial thickness burn wound.
14. The method of claim 9 , wherein said nanoemulsion comprises:
a) water;
b) polyoxyethylenesorbitan monolaurate;
c) glycerol or ethanol;
d) oil;
e) dimethyl benzyl ammonium chloride; and
f) ethylenediaminetetraacetic acid (EDTA).
15. The method of claim 9 , wherein said nanoemulsion comprises:
a) water;
b) a non-ionic surfactant selected from the group consisting of polyoxyethylenesorbitan monolaurate, polyoxyethylenesorbitan monooleate, and a poloxamer;
c) glycerol or ethanol;
d) oil;
e) a cationic surfactant selected from the group consisting of cetylpyridinium chloride (CPC), benzalkonium chloride, and alkyl dimethyl benzyl ammonium chloride; and
f) ethylenediaminetetraacetic acid (EDTA).
16. The method of claim 9 , wherein said nanoemulsion has a mean particle size of 0.2-0.8 microns.
17. The method of claim 9 , wherein said nanoemulsion has a mean particle size less than 0.5 microns.
18. The method of claim 9 , wherein said composition is co-administered with an antimicrobial agent.
19. The method of claim 18 , wherein said antimicrobial agent is an antibiotic.
20. The method of claim 9 , wherein said nanoemulsion comprises:
a) water;
b) 0.05-10.0% polyoxyethylene sorbitan monolaurate;
c) 3-15% glycerol;
d) oil;
e) 0.001-5.0% benzalkonium chloride; and
f) ethylenediaminetetraacetic acid (EDTA).